Primary Hyperparathyroidism

Table of Contents

1. Overview
2. Epidemiology
3. Causes and Pathogenesis
4. Clinical Presentation
5. Diagnosis and Laboratory Findings
6. Indications for Surgery
7. Medical Management
8. Prognosis and Complications
9. Key Research Papers
10. Connections
11. Featured Videos

Overview

Primary hyperparathyroidism (PHPT) is a disorder of calcium metabolism caused by autonomous, unsuppressed overproduction of parathyroid hormone (PTH) from one or more parathyroid glands. The result is chronic elevation of serum calcium — hypercalcemia — that persists because the normal feedback loop suppressing PTH release in the setting of high calcium is broken. PHPT is the most common cause of hypercalcemia in outpatients, accounting for roughly half of all cases seen in ambulatory care. By contrast, malignancy (bone metastases, PTHrP secretion) is the most common cause of hypercalcemia in hospitalized patients, a practical distinction that shapes clinical decision-making whenever elevated calcium is discovered.

Understanding PHPT requires familiarity with parathyroid anatomy and PTH physiology. The parathyroid glands are four small (25–40 mg each), tan-colored endocrine glands embedded in or near the posterior thyroid capsule. They arise from the pharyngeal pouches during embryonic development: the superior pair derives from the fourth pharyngeal pouch alongside the lateral thyroid anlage, while the inferior pair derives from the third pharyngeal pouch together with the thymus. This developmental origin explains why ectopic inferior glands occasionally migrate into the mediastinum alongside the thymus — a critical surgical consideration when a parathyroid adenoma cannot be localized in the neck.

PTH is secreted by chief cells of the parathyroid glands in response to a fall in ionized calcium, sensed by the calcium-sensing receptor (CaSR) on the cell surface. PTH raises serum calcium through three coordinated mechanisms:

1. Skeletal mobilization — PTH stimulates osteoblasts to release RANKL, which drives osteoclast activation and bone resorption, liberating calcium and phosphate from the mineralized matrix into the circulation.
2. Renal calcium reabsorption — PTH increases calcium reabsorption in the distal convoluted tubule, reducing urinary calcium losses, while simultaneously promoting phosphaturia in the proximal tubule (lowering serum phosphate, which reciprocally raises ionized calcium).
3. Activation of vitamin D — PTH stimulates renal 1-alpha-hydroxylase, converting 25-hydroxyvitamin D (25-OH-D) to 1,25-dihydroxyvitamin D (calcitriol, 1,25-OH-D3), the biologically active form. Calcitriol acts on intestinal epithelium to increase active absorption of both calcium and phosphate from the diet.

In PHPT, this entire calcium-raising axis is tonically activated in a manner that is not appropriately suppressed by the resulting hypercalcemia. The hallmark biochemical finding is elevated PTH that is not suppressed (and is often frankly elevated) despite serum calcium above the normal range. This distinguishes PHPT from virtually all other causes of hypercalcemia, in which PTH is appropriately low or undetectable.

PHPT predominantly affects women over the age of 50, especially postmenopausal women. The postmenopausal state is important because estrogen normally suppresses osteoclast activity; its loss in menopause amplifies the skeletal effects of excess PTH, accelerating bone turnover and worsening bone mineral density loss.

Back to Table of Contents

Epidemiology

Primary hyperparathyroidism is one of the most common endocrine disorders encountered in clinical practice. Population-based studies from Rochester, Minnesota — the most extensively studied cohort — estimate a prevalence of approximately 0.1 to 0.3% in the general adult population, though some estimates reach 1% in older women when modern sensitive assays are used. Annual incidence is approximately 66 per 100,000 persons in the United States, with higher rates in women and older age groups.

The female-to-male ratio is approximately 3:1, a disparity that widens further after menopause. The peak incidence occurs in women in their fifth through seventh decades, corresponding to the postmenopausal window when declining estrogen removes its protective influence on bone and amplifies the clinical consequences of PTH excess. Men tend to present at slightly younger ages, often with more symptomatic disease.

The clinical presentation of PHPT has shifted dramatically over the past five decades. Before the routine inclusion of serum calcium in automated chemistry panels (multiphasic screening introduced in the early 1970s), most patients presented with advanced symptomatic disease — nephrolithiasis, osteitis fibrosa cystica, or classic neuromuscular symptoms. Today, an estimated 80% of newly diagnosed PHPT patients are asymptomatic, discovered incidentally when routine blood work reveals hypercalcemia. This shift toward asymptomatic presentation has prompted ongoing debate about which patients truly benefit from parathyroidectomy versus observation.

Racial and ethnic variation exists: PHPT appears less prevalent in Black Americans in some series, though this may reflect underdiagnosis or differential screening rather than true biological differences. Internationally, the condition is recognized across all populations, with comparable rates reported in European cohorts.

Vitamin D deficiency is common among patients with PHPT and can mask the degree of hypercalcemia. When vitamin D-deficient patients with PHPT receive vitamin D supplementation, serum calcium may rise as the substrate for calcitriol production becomes available — a paradoxical but expected response that clinicians must anticipate.

Back to Table of Contents

Causes and Pathogenesis

PHPT arises from abnormal proliferation of parathyroid cells that have escaped the normal feedback regulation linking PTH secretion to serum calcium. The distribution of underlying pathology is well characterized:

• Solitary adenoma (85%) — a benign monoclonal proliferation of chief cells within a single enlarged gland, typically 0.5 to 5 grams, while the remaining three glands are normal or suppressed. The adenoma retains a rim of normal parathyroid tissue at its periphery, distinguishing it from carcinoma.
• Multigland hyperplasia (10–15%) — diffuse enlargement of all four glands, often polyclonal in origin, associated with genetic syndromes (see below) or occurring sporadically. Surgery requires removal of three-and-a-half glands or total parathyroidectomy with autotransplantation.
• Double adenoma (approximately 4%) — two glands harbor independent adenomas while the other two are normal. Increasingly recognized with improved intraoperative PTH monitoring.
• Parathyroid carcinoma (<1%) — malignant transformation with local invasion, vascular invasion, and capsular breach; often presents with markedly elevated calcium (>14 mg/dL) and very high PTH. Associated with CDC73 (HRPT2) gene mutations encoding parafibromin.

Molecular Pathogenesis

Two major molecular pathways drive parathyroid adenoma formation. The first involves the CCND1 gene (PRAD1 oncogene) encoding cyclin D1, a cell-cycle regulator. In approximately 20–40% of sporadic adenomas, cyclin D1 is overexpressed due to a pericentromeric inversion on chromosome 11 that places the CCND1 coding sequence under the PTH gene promoter — resulting in constitutive cyclin D1 overexpression, accelerated G1/S cell-cycle progression, and clonal outgrowth. This was the first oncogene identified in parathyroid neoplasia.

The second major pathway involves loss-of-function mutations in the MEN1 gene on chromosome 11q13, which encodes menin, a tumor suppressor protein involved in histone methylation, transcriptional regulation, and genomic stability. MEN1 mutations are found in nearly all patients with Multiple Endocrine Neoplasia type 1 and in approximately 15–20% of sporadic adenomas as a somatic (non-germline) event. Loss of the remaining wild-type allele (classic two-hit Knudson model) permits uncontrolled parathyroid cell growth.

Genetic Syndromes

PHPT is a defining component of several inherited endocrine tumor syndromes:

• Multiple Endocrine Neoplasia type 1 (MEN1) — autosomal dominant germline MEN1 mutation; PHPT affects ~95% of MEN1 patients (most common manifestation), typically multigland hyperplasia presenting in the third to fourth decade; also includes pituitary adenomas and pancreatic/duodenal neuroendocrine tumors.
• Multiple Endocrine Neoplasia type 2A (MEN2A) — autosomal dominant RET proto-oncogene mutation; PHPT occurs in ~20–30% of MEN2A patients alongside medullary thyroid carcinoma and pheochromocytoma; typically milder hyperplasia.
• Hyperparathyroidism-jaw tumor syndrome (HPT-JT) — CDC73 germline mutation; PHPT with ossifying jaw fibromas and high risk of parathyroid carcinoma (~15%).
• Familial isolated hyperparathyroidism (FIHP) — germline mutations in MEN1, CDC73, or CASR; PHPT without other syndromic features.

Genetic testing is recommended for patients under age 40 presenting with PHPT, those with multigland disease, and those with a family history suggesting an inherited syndrome.

Back to Table of Contents

Clinical Presentation

The traditional mnemonic for the clinical features of PHPT — "bones, stones, groans, and psychic moans" — captures the four organ systems most affected by chronic PTH excess and hypercalcemia. While this mnemonic dates to an era when symptomatic disease was the norm, it remains a practical teaching framework. Today, approximately 80% of newly diagnosed patients are asymptomatic (or minimally symptomatic), found incidentally on routine chemistry panels. The remaining 20% present with symptoms referable to one or more of these four domains.

Renal Manifestations ("Stones")

The kidney is the most commonly affected organ in symptomatic PHPT. Excess filtered calcium overwhelms tubular reabsorption, producing hypercalciuria in approximately 40% of patients. Consequences include:

• Nephrolithiasis — calcium oxalate or calcium phosphate kidney stones in 15–20% of symptomatic patients; recurrent stones in a middle-aged woman should always prompt calcium and PTH measurement.
• Nephrocalcinosis — diffuse calcium deposition within the renal parenchyma, visible on imaging; indicates more severe or longstanding hypercalciuria and correlates with progressive renal insufficiency.
• Polyuria and polydipsia — hypercalcemia impairs renal tubular responsiveness to antidiuretic hormone (nephrogenic diabetes insipidus-like effect), producing a concentrating defect with increased urine output and compensatory thirst.
• Renal insufficiency — reduced eGFR from nephrocalcinosis, recurrent obstruction from stones, or direct tubular toxicity; eGFR <60 mL/min/1.73m² is an indication for parathyroidectomy in asymptomatic patients.

Skeletal Manifestations ("Bones")

Excess PTH drives a high bone-turnover state with net resorption exceeding formation. The bone disease of PHPT spans a spectrum from subclinical BMD loss to the overt osteitis fibrosa cystica of severe longstanding disease:

• Reduced bone mineral density — preferentially affects cortical bone (distal radius) more than trabecular bone (lumbar spine) in mild PHPT, because PTH transiently spares trabecular bone through its anabolic effects on trabecular microarchitecture. This cortical predominance is clinically important — standard spine DXA may underestimate skeletal risk.
• Subperiosteal bone resorption — pathognomonic radiographic finding on plain X-ray of the hands: irregular resorption along the radial aspect of the middle phalanges of the index and middle fingers; "lace-like" cortical pattern.
• Osteitis fibrosa cystica — severe form with replacement of normal bone by fibrous tissue and giant-cell-rich "brown tumors" (aggregates of osteoclasts and hemosiderin-laden macrophages); now rare in high-income countries due to early diagnosis.
• "Salt-and-pepper" skull — granular demineralization of the calvarium visible on lateral skull X-ray; another classic radiographic sign of severe PHPT.
• Pathological fractures — in advanced disease; vertebral fractures may occur even with relatively preserved DXA scores due to cortical thinning.

Gastrointestinal Manifestations ("Groans")

• Constipation — hypercalcemia reduces smooth muscle contractility, slowing intestinal transit; one of the most common nonspecific complaints in PHPT.
• Nausea, vomiting, and anorexia — particularly with acute hypercalcemic crises (calcium >12–14 mg/dL).
• Peptic ulcer disease — calcium stimulates gastrin secretion, increasing gastric acid output; the association between PHPT and peptic ulcers is well established, particularly in the context of MEN1 where concurrent gastrinoma (Zollinger-Ellison syndrome) may coexist.
• Acute pancreatitis — hypercalcemia activates trypsinogen to trypsin within pancreatic ductal cells; recurrent unexplained pancreatitis should prompt evaluation for PHPT.

Neuropsychiatric Manifestations ("Psychic Moans")

• Cognitive impairment and "brain fog" — difficulty concentrating, poor short-term memory, and mental slowing are among the most common patient complaints in mild PHPT, and often improve or resolve after parathyroidectomy.
• Depression and anxiety — elevated prevalence of mood disorders in PHPT; mechanisms include direct effects of PTH and calcium on neuronal signaling, altered monoamine neurotransmitter function, and disrupted sleep architecture.
• Fatigue and muscle weakness — proximal myopathy with symmetric weakness in the thighs and upper arms; hypercalcemia impairs neuromuscular junction function and mitochondrial energy production in muscle.
• Severe neuropsychiatric manifestations — in hypercalcemic crisis (calcium >14 mg/dL): lethargy, confusion, stupor, and coma; a medical emergency requiring urgent hydration and calcium-lowering treatment.

Cardiovascular Manifestations

An increasingly recognized domain not captured in the traditional mnemonic. Chronic PTH excess and hypercalcemia are associated with hypertension (in approximately 40–50% of PHPT patients), left ventricular hypertrophy, vascular calcification, and increased risk of cardiovascular events. These associations are partially reversible after parathyroidectomy, providing additional rationale for surgical intervention even in "asymptomatic" patients.

Back to Table of Contents

Diagnosis and Laboratory Findings

The diagnosis of PHPT rests on the biochemical demonstration of hypercalcemia with an inappropriately non-suppressed PTH. The combination is almost pathognomonic — in virtually every other cause of hypercalcemia, PTH is appropriately suppressed.

Core Laboratory Findings

• Elevated serum calcium — total calcium above the laboratory's upper limit of normal (typically 10.2–10.5 mg/dL depending on laboratory); must be confirmed on at least two separate occasions. Always correct for serum albumin: corrected calcium = measured calcium + 0.8 × (4.0 − albumin g/dL). Ionized calcium measurement eliminates albumin confounding.
• Elevated or inappropriately normal PTH — intact PTH (measured by two-site immunoradiometric or immunochemiluminescent assay) is elevated or in the upper half of the normal range despite hypercalcemia. A suppressed PTH (<20 pg/mL) effectively rules out PHPT and points toward malignancy, vitamin D toxicity, or granulomatous disease.
• Low-normal serum phosphate — PTH promotes renal phosphate wasting; serum phosphate is characteristically at or below the lower limit of normal in PHPT.
• Elevated 24-hour urine calcium — hypercalciuria (>250 mg/day in women, >300 mg/day in men) reflects the filtered calcium load exceeding tubular reabsorption; measured to assess stone risk and to help distinguish PHPT from familial hypocalciuric hypercalcemia (see below).
• Low 25-hydroxyvitamin D — vitamin D deficiency is common in PHPT (it can exacerbate secondary hyperparathyroidism overlay) and may blunt hypercalcemia; correction with vitamin D supplementation should be done cautiously under specialist supervision.
• Elevated alkaline phosphatase — a marker of bone turnover; elevated in patients with significant skeletal disease.
• Elevated serum chloride, low bicarbonate — PTH inhibits proximal tubular bicarbonate reabsorption, producing a mild hyperchloremic metabolic acidosis; the chloride-to-phosphate ratio >33 is a classic (though insensitive) bedside clue.

Normocalcemic PHPT

A recognized variant — normocalcemic primary hyperparathyroidism — features persistently normal total and ionized calcium with elevated PTH after excluding all causes of secondary hyperparathyroidism (vitamin D deficiency, renal disease, malabsorption, medications). These patients may represent early PHPT before hypercalcemia develops, and some progress to overt disease over time. Management remains controversial and individualized.

Differential Diagnosis: Familial Hypocalciuric Hypercalcemia (FHH)

FHH is a benign autosomal dominant condition caused by loss-of-function mutations in the calcium-sensing receptor gene (CASR), resulting in a higher calcium set-point at the parathyroid glands and kidneys. Like PHPT, FHH presents with hypercalcemia and a non-suppressed PTH — but the kidney retains calcium avidly. The distinguishing test is the calcium-to-creatinine clearance ratio (CCCR):

CCCR = (urine Ca × serum Cr) / (serum Ca × urine Cr)

A CCCR <0.01 strongly suggests FHH; a CCCR >0.02 favors PHPT. FHH is benign, self-limiting, does not cause nephrolithiasis or osteitis fibrosa cystica, and does not require surgery. Performing parathyroidectomy on a patient with FHH is an avoidable error that does not correct the hypercalcemia. Family history and genetic testing (CASR mutation analysis) confirm the diagnosis.

Parathyroid Localization Studies

Localization is not required for diagnosis but is essential for surgical planning. The goal is to identify the culprit gland(s) so minimally invasive parathyroidectomy (MIP) can replace bilateral four-gland exploration in appropriate cases.

• Sestamibi scan (technetium-99m-sestamibi) — the most widely used first-line localization study. Sestamibi accumulates preferentially in hypercellular parathyroid tissue (due to high mitochondrial content) and washes out more slowly than from thyroid tissue; single-photon emission CT (SPECT) improves sensitivity. Sensitivity approximately 80–85% for solitary adenoma; lower for multigland disease.
• Four-dimensional CT (4D-CT) — multidetector CT with pre-contrast, arterial, venous, and delayed phases; identifies the adenoma by its characteristic enhancement pattern and precise anatomical location. Increasingly preferred at high-volume centers; useful when sestamibi is negative or discordant.
• Neck ultrasound — operator-dependent; best for anterior neck adenomas; cannot visualize retrosternal or intrathymic glands; combined with sestamibi, concordant results substantially increase surgical success.
• MRI and PET-choline — reserved for re-operative cases or discordant conventional imaging.

Back to Table of Contents

Indications for Surgery

Parathyroidectomy is the only curative treatment for PHPT. It is unambiguously indicated for all symptomatic patients — those with nephrolithiasis, osteitis fibrosa cystica, significant neuromuscular symptoms, or hypercalcemic crisis. The more nuanced question is whether and when to operate on the growing majority of asymptomatic patients.

International guidelines (most recently updated in 2014 and 2022) define specific criteria for recommending parathyroidectomy in asymptomatic PHPT. Any one of the following is sufficient:

• Age under 50 years — younger patients have decades of cumulative exposure to PTH excess, with progressive skeletal and renal consequences; surgery is recommended regardless of biochemical severity.
• Serum calcium >1 mg/dL above the upper limit of normal — e.g., >11.2 mg/dL if the ULN is 10.2 mg/dL; indicates more biologically active disease.
• Reduced bone mineral density — DXA T-score ≤ −2.5 at any skeletal site (lumbar spine, hip, or distal one-third radius); the distal radius is particularly important in PHPT because cortical bone is disproportionately affected.
• Vertebral fracture on imaging — clinically silent vertebral fractures detected by vertebral fracture assessment (VFA) or spinal X-ray indicate skeletal fragility even when DXA T-scores are not at the threshold.
• Reduced renal function — eGFR <60 mL/min/1.73m²; indicates established renal damage from hypercalcemia or nephrocalcinosis.
• Nephrolithiasis or nephrocalcinosis on imaging — even if no prior stone episode was clinically apparent; renal ultrasound or CT should be obtained as part of the initial evaluation.
• 24-hour urine calcium >400 mg/day — combined with elevated stone risk profile on biochemical stone risk panel.

Surgical Technique

The preferred operation in patients with concordant preoperative localization (positive sestamibi and/or 4D-CT agreeing on a single gland) is minimally invasive parathyroidectomy (MIP) — targeted removal of the identified adenoma through a small focused incision, typically under local or regional anesthesia. MIP requires intraoperative PTH monitoring to confirm cure: a >50% drop in PTH within 10 minutes of gland removal (Miami criterion) predicts successful cure with sensitivity and specificity exceeding 97%.

When localization is negative or discordant, or when multigland disease is suspected (MEN1, familial HPT, normalization of PTH not achieved after removal of one gland), bilateral four-gland exploration under general anesthesia remains the gold standard. An experienced endocrine surgeon can identify all four glands in over 95% of cases.

Intraoperative PTH monitoring has transformed parathyroid surgery from a procedure requiring bilateral exploration to a targeted, outpatient operation at high-volume centers. The half-life of intact PTH is approximately 3–5 minutes, making rapid intraoperative measurement feasible with point-of-care analyzers.

Patient Selection and Shared Decision-Making

For patients with asymptomatic PHPT who do not meet guideline criteria, the decision between surgery and surveillance involves individualized discussion of surgical risk, patient preference, access to an experienced endocrine surgeon, and the trajectory of disease. Many guideline authors note that "asymptomatic" is a relative term — patients often report quality-of-life improvements (improved cognition, mood, and energy) after parathyroidectomy even when they denied specific symptoms preoperatively.

Back to Table of Contents

Medical Management

For patients who are not candidates for surgery — due to comorbidities, anesthesia risk, or personal preference — or for those who meet observation criteria, medical management focuses on preventing disease progression and protecting target organs. Medical therapy does not cure PHPT; it manages its consequences while the underlying autonomous PTH secretion continues.

Cinacalcet (Calcimimetic Therapy)

Cinacalcet (Sensipar) is an allosteric activator of the calcium-sensing receptor on parathyroid chief cells. By sensitizing the CaSR to ambient calcium, it effectively lowers the calcium set-point and reduces PTH secretion, normalizing serum calcium in approximately 70–80% of PHPT patients. Key points:

• Cinacalcet lowers serum calcium effectively but does not reduce gland size, reverse bone loss, or cure the underlying disease — the parathyroid adenoma remains.
• It does not reduce 24-hour urine calcium and does not decrease nephrolithiasis risk (in contrast to parathyroidectomy).
• It does not improve BMD — bisphosphonates must be added separately for skeletal protection.
• Primary role: managing symptomatic hypercalcemia in inoperable patients, or bridging to surgery in severe hypercalcemia.
• Common side effects: nausea, vomiting, and hypocalcemia; dose titrated from 30 mg twice daily.

Bisphosphonates

Bisphosphonates (alendronate, risedronate, zoledronic acid) inhibit osteoclast-mediated bone resorption. In PHPT, they preserve and modestly improve BMD, particularly at the lumbar spine, without significantly altering serum calcium or PTH levels. They are appropriate for patients with osteoporosis who are not surgical candidates. Alendronate 70 mg weekly is the most commonly used regimen in this context.

Lifestyle and Dietary Guidance

• Hydration — maintaining high fluid intake (2–3 liters/day) dilutes urinary calcium and reduces stone risk; particularly important in hot climates or during exercise.
• Dietary calcium — contrary to intuition, severe dietary calcium restriction is not recommended. Restricting calcium from food reduces intestinal binding of oxalate, paradoxically increasing urinary oxalate and stone risk. Moderate calcium intake (1000–1200 mg/day from food) is appropriate.
• Avoid dehydration and immobilization — both worsen hypercalcemia; prolonged bed rest mobilizes calcium from bone.
• Thiazide diuretics — contraindicated in PHPT; thiazides increase renal calcium reabsorption, worsening hypercalcemia. If a patient requires a diuretic, a loop diuretic (furosemide) is preferred, though it should be used with adequate hydration to avoid paradoxical hypercalcemia from volume depletion.
• Lithium — raises PTH levels and can precipitate or worsen PHPT; if lithium must be continued for psychiatric indications, close calcium and PTH monitoring is required.

Surveillance Protocol for Asymptomatic PHPT

Patients under observation should be monitored annually with:

• Serum calcium and PTH
• Serum creatinine and estimated GFR
• DXA (BMD at three sites: lumbar spine, hip, distal radius) every 1–2 years
• Renal ultrasound every 2–3 years (or sooner if symptoms develop)
• Vertebral fracture assessment if spinal symptoms arise

Any development of a surgical indication warrants prompt referral for parathyroidectomy. Approximately one-third of patients under observation will develop an indication for surgery within 15 years.

Back to Table of Contents

Prognosis and Complications

The prognosis after successful parathyroidectomy is excellent. Cure rates exceed 95% at high-volume endocrine surgery centers with an experienced parathyroid surgeon. Serum calcium typically normalizes within hours of successful gland removal, confirmed by intraoperative PTH drop. Long-term recurrence rates for sporadic adenoma are under 1–2% per decade of follow-up. Patients with MEN1 have a significantly higher recurrence rate due to the multigland nature of the disease.

Complications of Untreated PHPT

• Progressive nephrolithiasis — ongoing hypercalciuria and stone formation; risk of obstructive nephropathy and permanent renal damage.
• Osteoporosis progression — continued bone loss accelerates fracture risk; cortical bone at the distal radius is particularly vulnerable.
• Cardiovascular disease — hypertension, left ventricular hypertrophy, aortic valve calcification, and coronary artery calcification are all more prevalent in PHPT; whether these risks fully normalize after surgery remains an active research question, but early surgical intervention shows the most benefit.
• Hypercalcemic crisis — triggered by dehydration, immobilization, diuretics, or intercurrent illness; calcium can rise acutely above 14–15 mg/dL, causing altered consciousness and multi-organ failure; managed with aggressive IV saline hydration, calcitonin (rapid but short-lived effect), bisphosphonate infusion, and urgent parathyroidectomy or dialysis in extremis.

Surgical Complications

• Recurrent laryngeal nerve injury — the most feared surgical complication; permanent vocal cord paralysis in less than 1% of cases at experienced centers; transient hoarseness in 1–3%.
• Hypoparathyroidism — transient hypocalcemia from parathyroid gland bruising or devascularization during dissection; permanent hypoparathyroidism in less than 1–2% with experienced surgeons; requires lifelong calcium and calcitriol supplementation when permanent.
• Hungry bone syndrome — the most significant metabolic complication after parathyroidectomy in patients with significant skeletal disease. After decades of PTH-driven osteoclast excess, the abrupt withdrawal of PTH following gland removal unmasks a profound anabolic rebound: osteoblasts (previously suppressed relative to osteoclasts) now avidly mineralize the demineralized bone matrix. This rapid bone remineralization consumes massive quantities of calcium, phosphate, and magnesium from the circulation, producing severe, prolonged hypocalcemia that can last weeks to months. Management requires high-dose oral calcium supplementation (often 2–4 grams elemental calcium per day) plus calcitriol; severe cases require IV calcium gluconate infusions. Risk factors include preoperative elevated alkaline phosphatase, large adenoma weight, high preoperative PTH, and preexisting vitamin D deficiency.

Outcomes After Parathyroidectomy

Beyond normalization of calcium, successful parathyroidectomy produces measurable improvements across multiple domains:

• Bone — BMD increases at the lumbar spine (3–5%), hip (2–3%), and distal radius (1–2%) in the first 1–3 years after surgery; progressive skeletal protection continues for years.
• Renal — stone recurrence decreases substantially; eGFR stabilizes or improves in those with early renal impairment.
• Neuropsychiatric — improved cognition, reduced depression scores, and enhanced quality-of-life measures in most prospective studies; effects most pronounced in patients with preoperative cognitive or mood symptoms.
• Cardiovascular — blood pressure may improve; data on hard cardiovascular endpoints (MI, stroke) are less definitive but suggest benefit from early surgery.

Back to Table of Contents

Key Research Papers

1. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014. PMID 27540808
2. Bilezikian JP, Khan AA, Potts JT Jr, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Bone Miner Res 2009. PMID 19837826
3. Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 2017. PMID 31355878
4. Perrier ND. Asymptomatic hyperparathyroidism: a medical misnomer? Surgery 2005. PMID 23344222
5. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 2013. PMID 28414387
6. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006. PMID 16738440
7. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014. PMID 25969234
8. Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med 2011. PMID 18625682
9. Agarwal G, Nanda G, Kapoor A, et al. Cardiovascular dysfunction in symptomatic primary hyperparathyroidism and its reversal after curative parathyroidectomy. World J Surg 2013. PMID 26949807
10. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005. PMID 11948263
11. Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg 2011. PMID 23609950
12. Insogna KL. Primary hyperparathyroidism. N Engl J Med 2018. PMID 29924958

PubMed Topic Searches

1. Primary hyperparathyroidism diagnosis and management
2. Asymptomatic hyperparathyroidism surgery guidelines
3. Minimally invasive parathyroidectomy outcomes
4. Cinacalcet primary hyperparathyroidism clinical trial
5. Hungry bone syndrome after parathyroidectomy
6. Familial hypocalciuric hypercalcemia calcium-sensing receptor

Back to Table of Contents

Connections

• Hyperparathyroidism — general overview of all hyperparathyroidism types including primary, secondary, and tertiary
• Secondary Hyperparathyroidism — compensatory PTH elevation driven by chronic kidney disease or vitamin D deficiency; contrasts with autonomous excess in PHPT
• Hypoparathyroidism — insufficient PTH causing hypocalcemia; the biochemical mirror image of PHPT; a risk after parathyroid surgery
• Multiple Endocrine Neoplasia — MEN1 and MEN2A both include PHPT as a component; genetic testing indicated in young PHPT patients
• Osteoporosis — major skeletal complication of untreated PHPT; preferential cortical bone loss at the distal radius
• Lab Tests — serum calcium, intact PTH, 24-hour urine calcium, phosphate, alkaline phosphatase, and eGFR are the cornerstone laboratory panel in PHPT
• Calcium — calcium physiology, dietary sources, and normal homeostasis regulated by PTH and vitamin D
• Endocrinology Conditions — full index of endocrine disorders covered on this site

Back to Table of Contents

Featured Videos